Edgar E. Lara-Ramírez
Instituto Politécnico Nacional
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Edgar E. Lara-Ramírez.
BioMed Research International | 2014
Edgar E. Lara-Ramírez; Ma Isabel Salazar; María de Jesús López-López; Juan Santiago Salas-Benito; Alejandro Sánchez-Varela; Xianwu Guo
The increasing number of dengue virus (DENV) genome sequences available allows identifying the contributing factors to DENV evolution. In the present study, the codon usage in serotypes 1–4 (DENV1–4) has been explored for 3047 sequenced genomes using different statistics methods. The correlation analysis of total GC content (GC) with GC content at the three nucleotide positions of codons (GC1, GC2, and GC3) as well as the effective number of codons (ENC, ENCp) versus GC3 plots revealed mutational bias and purifying selection pressures as the major forces influencing the codon usage, but with distinct pressure on specific nucleotide position in the codon. The correspondence analysis (CA) and clustering analysis on relative synonymous codon usage (RSCU) within each serotype showed similar clustering patterns to the phylogenetic analysis of nucleotide sequences for DENV1–4. These clustering patterns are strongly related to the virus geographic origin. The phylogenetic dependence analysis also suggests that stabilizing selection acts on the codon usage bias. Our analysis of a large scale reveals new feature on DENV genomic evolution.
PLOS ONE | 2011
Edgar E. Lara-Ramírez; Aldo Segura-Cabrera; Xianwu Guo; Gongxin Yu; Carlos Armando García-Pérez; Mario A. Rodríguez-Pérez
Background Helicobacter pylori has a reduced genome and lives in a tough environment for long-term persistence. It evolved with its particular characteristics for biological adaptation. Because several H. pylori genome sequences are available, comparative analysis could help to better understand genomic adaptation of this particular bacterium. Principal Findings We analyzed nine H. pylori genomes with emphasis on microevolution from a different perspective. Inversion was an important factor to shape the genome structure. Illegitimate recombination not only led to genomic inversion but also inverted fragment duplication, both of which contributed to the creation of new genes and gene family, and further, homological recombination contributed to events of inversion. Based on the information of genomic rearrangement, the first genome scaffold structure of H. pylori last common ancestor was produced. The core genome consists of 1186 genes, of which 22 genes could particularly adapt to human stomach niche. H. pylori contains high proportion of pseudogenes whose genesis was principally caused by homopolynucleotide (HPN) mutations. Such mutations are reversible and facilitate the control of gene expression through the change of DNA structure. The reversible mutations and a quasi-panmictic feature could allow such genes or gene fragments frequently transferred within or between populations. Hence, pseudogenes could be a reservoir of adaptation materials and the HPN mutations could be favorable to H. pylori adaptation, leading to HPN accumulation on the genomes, which corresponds to a special feature of Helicobacter species: extremely high HPN composition of genome. Conclusion Our research demonstrated that both genome content and structure of H. pylori have been highly adapted to its particular life style.
Molecules | 2017
Karla Fabiola Chacón-Vargas; Benjamín Nogueda-Torres; Luvia Enid Sánchez-Torres; Erick Suárez-Contreras; Juan Carlos Villalobos-Rocha; Yuridia Torres-Martinez; Edgar E. Lara-Ramírez; Giulia Fiorani; R. Krauth-Siegel; Maria Laura Bolognesi; Antonio Monge; Gildardo Rivera
Chagas disease or American trypanosomiasis is a worldwide public health problem. In this work, we evaluated 26 new propyl and isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential trypanocidal agents. Additionally, molecular docking and enzymatic assays on trypanothione reductase (TR) were performed to provide a basis for their potential mechanism of action. Seven compounds showed better trypanocidal activity on epimastigotes than the reference drugs, and only four displayed activity on trypomastigotes; T-085 was the lead compound with an IC50 = 59.9 and 73.02 µM on NINOA and INC-5 strain, respectively. An in silico analysis proposed compound T-085 as a potential TR inhibitor with better affinity than the natural substrate. Enzymatic analysis revealed that T-085 inhibits parasite TR non-competitively. Compound T-085 carries a carbonyl, a CF3, and an isopropyl carboxylate group at 2-, 3- and 7-position, respectively. These results suggest the chemical structure of this compound as a good starting point for the design and synthesis of novel trypanocidal derivatives with higher TR inhibitory potency and lower toxicity.
PLOS Neglected Tropical Diseases | 2013
Edgar E. Lara-Ramírez; Mario A. Rodríguez-Pérez; Miguel Á. Pérez-Rodríguez; Monsuru Adebayo Adeleke; María E. Orozco-Algarra; Juan I. Arrendondo-Jiménez; Xianwu Guo
Background In Latin America, there are 13 geographically isolated endemic foci distributed among Mexico, Guatemala, Colombia, Venezuela, Brazil and Ecuador. The communities of the three endemic foci found within Mexico have been receiving ivermectin treatment since 1989. In this study, we predicted the trend of occurrence of cases in Mexico by applying time series analysis to monthly onchocerciasis data reported by the Mexican Secretariat of Health between 1988 and 2011 using the software R. Results A total of 15,584 cases were reported in Mexico from 1988 to 2011. The data of onchocerciasis cases are mainly from the main endemic foci of Chiapas and Oaxaca. The last case in Oaxaca was reported in 1998, but new cases were reported in the Chiapas foci up to 2011. Time series analysis performed for the foci in Mexico showed a decreasing trend of the disease over time. The best-fitted models with the smallest Akaike Information Criterion (AIC) were Auto-Regressive Integrated Moving Average (ARIMA) models, which were used to predict the tendency of onchocerciasis cases for two years ahead. According to the ARIMA models predictions, the cases in very low number (below 1) are expected for the disease between 2012 and 2013 in Chiapas, the last endemic region in Mexico. Conclusion The endemic regions of Mexico evolved from high onchocerciasis-endemic states to the interruption of transmission due to the strategies followed by the MSH, based on treatment with ivermectin. The extremely low level of expected cases as predicted by ARIMA models for the next two years suggest that the onchocerciasis is being eliminated in Mexico. To our knowledge, it is the first study utilizing time series for predicting case dynamics of onchocerciasis, which could be used as a benchmark during monitoring and post-treatment surveillance.
Journal of Drug Targeting | 2017
Muhammad Kashif; Antonio Moreno-Herrera; Edgar E. Lara-Ramírez; Esther Ramírez-Moreno; Virgilio Bocanegra-García; Muhammad Ashfaq; Gildardo Rivera
Abstract Chagas is a lethal chronic disease that currently affects 8–10 million people worldwide, primarily in South and Central America. Trypanosoma cruzi trans-sialidase is an enzyme that is of vital importance for the survival of the parasite due to its key role in the transfer of sialic acid from the host to the parasite surface and it also helps the parasite combat the host’s immune system. This enzyme has no equivalent human enzyme; thus, it has become an interesting target for the development of inhibitors that combat the parasite. In this review, we summarize three classes of inhibitors (acceptor, donor and unrelated) with their inhibition values and their mode of action against this enzyme. Based on molecular docking, molecular dynamics and structure-activity relationship studies, it has been discovered that the molecules with –NH2, –OH and –COOH groups on an aromatic ring could be used as a scaffold for the development of new and potent trans-sialidase inhibitors due to their key interaction with active enzyme sites. In particular, carboxylic acid derivatives have importance over the sugar moiety due to their ease of synthesis and unique structure-activity relationship.
Molecules | 2017
Isidro Palos; Edgar E. Lara-Ramírez; Julio Cesar López-Cedillo; Carlos Armando García-Pérez; Muhammad Kashif; Virgilio Bocanegra-García; Benjamín Nogueda-Torres; Gildardo Rivera
Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi, which affects underdeveloped countries. The current drugs of choice are nifurtimox and benznidazole, but both have severe adverse effects and less effectivity in chronic infections; therefore, the need to discover new drugs is essential. A computer-guided drug repositioning method was applied to identify potential FDA drugs (approved and withdrawn) as cruzain (Cz) inhibitors and trypanocidal effects were confirmed by in vitro and in vivo studies. 3180 FDA drugs were virtually screened using a structure-based approach. From a first molecular docking analysis, a set of 33 compounds with the best binding energies were selected. Subsequent consensus affinity binding, ligand amino acid contact clustering analysis, and ranked position were used to choose four known pharmacological compounds to be tested in vitro. Mouse blood samples infected with trypomastigotes from INC-5 and NINOA strains were used to test the trypanocidal effect of four selected compounds. Among these drugs, one fibrate antilipemic (etofyllin clofibrate) and three β-lactam antibiotics (piperacillin, cefoperazone, and flucloxacillin) showed better trypanocidal effects (LC50 range 15.8–26.1 μg/mL) in comparison with benznidazole and nifurtimox (LC50 range 33.1–46.7 μg/mL). A short-term in vivo evaluation of these compounds showed a reduction of parasitemia in infected mice (range 90–60%) at 6 h, but this was low compared to benznidazole (50%). This work suggests that four known FDA drugs could be used to design and obtain new trypanocidal agents.
Archive | 2015
Mario A. Rodríguez-Pérez; Edgar E. Lara-Ramírez; Olga Real-Najarro; Thomas R. Unnasch
Onchocerciasis, a chronic, debilitating, poverty-promoting parasitic disease, is one of the five most common of the officially designated neglected tropical diseases. It has been found in 13 discrete foci distributed among six countries (Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela) in Latin America (LA). Onchocerciasis was brought to the Americas through the slave trade in the sixteenth century, was transmitted to the indigenous American population once introduced, and was then spread through migration. Since its discovery in LA, numerous efforts have been put forth to understand the epidemiology of the disease to control and eventually eliminate the disease. The establishment of public–private partnerships and the development of community wide mass distribution programs of Mectizan® (ivermectin, donated by Merck, Sharpe, and Dohme) have resulted in dramatic progress against onchocerciasis in all of the endemic foci of LA. Transmission has been interrupted in 11 of 13 foci in LA, including all foci in Colombia, Ecuador, Guatemala, and Mexico as well as in two of the three foci in Venezuela. Transmission remains active only in the two foci straddling the border between Brazil and Venezuela. This area is inhabited by the Yanomami tribe indigenous to the Amazonian forest, and evidence suggests that transmission has been suppressed in some Yanomami communities. Interruption of transmission in these Amazonian foci, the last active foci in LA, will require intensified efforts and cross-border collaboration, but once successful, will culminate in the complete elimination of this scourge from the Americas.
Viruses | 2013
Edgar E. Lara-Ramírez; Aldo Segura-Cabrera; Ma Isabel Salazar; Mario A. Rodríguez-Pérez; Xianwu Guo
The past pandemic strain H1N1 (A (H1N1)pdm09) has now become a common component of current seasonal influenza viruses. It has changed the pre-existing immunity of the human population to succeeding infections. In the present study, a total of 14,210 distinct sequences downloaded from National Center for Biotechnology Information (NCBI) database were used for the analysis. The epitope compositions in A (H1N1)pdm09, classic seasonal strains, swine strains as well as highly virulent avian strain H5N1, identified with the aid of the Immune Epitope DataBase (IEDB), were compared at genomic level. The result showed that A (H1N1) pdm09 contains the 90% of B-cell epitopes for broadly cross-reactive antibodies (EBCA), which is in consonance with the recent reports on the experimental identification of new epitopes or antibodies for this virus and the binding tests with influenza virus protein HA of different subtypes. Our analysis supports that high proportional EBCA depends on the epitope pattern of A (H1N1)pdm09 virus. This study may be helpful for better understanding of A (H1N1)pdm09 and the production of new influenza vaccines.
PLOS ONE | 2018
Noe Macias-Segura; Julio E. Castañeda-Delgado; Yadira Bastián; D. Santiago-Algarra; J. D. Castillo-Ortiz; A. L. Alemán-Navarro; E. Jaime-Sánchez; M. Gomez-Moreno; C. A. Saucedo-Toral; Edgar E. Lara-Ramírez; M. Zapata-Zuñiga; L. Enciso-Moreno; R. González-Amaro; C. Ramos-Remus; José Antonio Enciso-Moreno
Background Little is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed. Methods Whole blood total RNA was obtained from non-treated early RA patients with <1 year of evolution as well as from healthy first-degree relatives of patients with RA (FDR) classified as ACCP+ and ACCP- according to their antibodies serum levels against cyclic citrullinated peptides. Complementary RNA (cRNA) was synthetized and hybridized to high-density microarrays. Data was analyzed in Genespring Software and functional categories were assigned to a specific transcriptome identified in subjects with RA and FDR ACCP positive. Specific signaling pathways for genes associated to RA were identified. Gene expression was evaluated by qPCR. Receiver operating characteristic (ROC) analysis was used to evaluate these genes as biomarkers. Results A characteristic transcriptome of 551 induced genes and 4,402 repressed genes were identified in early RA patients. Bioinformatics analysis of the data identified a specific transcriptome in RA patients. Moreover, some overlapped transcriptional profiles between patients with RA and ACCP+ were identified, suggesting an up-regulated distinctive transcriptome from the preclinical stages up to progression to an early RA state. A total of 203 pathways have up-regulated genes that are shared between RA and ACCP+. Some of these genes show potential to be used as progression biomarkers for early RA with area under the curve of ROC > 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways. Conclusion The presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.
Current Microbiology | 2014
Yajuan Fu; Reyna Cristina Zepeda-Gurrola; Germán Rubén Aguilar-Gutiérrez; Edgar E. Lara-Ramírez; Erick de Jesús De Luna-Santillana; Isabel Cristina Rodríguez-Luna; Alejandro Sánchez-Varela; Ricardo Carreño-López; Mario A. Rodríguez-Pérez; Yolanda López-Vidal; Xianwu Guo